Rethinking Lung Cancer Screening: AI Nodule Detection and Diagnosis Outperforms Radiologists, Leading Models, and Standards Beyond Size and Growth

Sylvain Bodard, Pierre Baudot, Benjamin Renoust, Charles Voyton, Gwendoline De Bie, Ezequiel Geremia, Van-Khoa Le, Danny Francis, Pierre-Henri Siot, Yousra Haddou, Vincent Bobin, Jean-Christophe Brisset, Carey C. Thomson, Valérie Bourdès, Benoit Huet · 2025

Read Rethinking Lung Cancer Screening: AI Nodule Detection and Diagnosis Outperforms Radiologists, Leading Models, and Standards Beyond Size and Growth by Sylvain Bodard, Pierre Baudot, Benjamin Renoust, Charles Voyton, Gwendoline De Bie, Ezequiel Geremia, Van-Khoa Le, Danny Francis, Pierre-Henri Siot, Yousra Haddou, Vincent Bobin, Jean-Christophe Brisset, Carey C. Thomson, Valérie Bourdès, Benoit Huet (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/arxiv-2512-00281.txt.

Introduction

Finding lung cancer early saves lives, but screening rules based on nodule size and growth can delay diagnosis. Sylvain Bodard and a large team present an AI system that rethinks lung cancer screening in 2025. The system works directly on low-dose CT scans.

Instead of waiting for growth, the AI performs both detection and malignancy diagnosis at the level of each nodule. The authors report performance beyond radiologists, leading models, and standards based on size and growth. If such results hold in wider trials, screening could flag dangerous nodules at the first scan rather than months later. Low-dose scans are noisier than standard CT, which makes nodule-level diagnosis harder.

Catalog record

CREATORSylvain Bodard, Pierre Baudot, Benjamin Renoust, Charles Voyton, Gwendoline De Bie, Ezequiel Geremia, Van-Khoa Le, Danny Francis, Pierre-Henri Siot, Yousra Haddou, Vincent Bobin, Jean-Christophe Brisset, Carey C. Thomson, Valérie Bourdès, Benoit Huet
YEAR2025
COLLECTIONPAPERS
FORMATTXT
FILE SIZE119 KB
VERSION1.0
LICENSEhttp://creativecommons.org/licenses/by/4.0/
RIGHTSCC BY
SOURCEarXiv

Source: https://arxiv.org/abs/2512-00281

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Rethinking Lung Cancer Screening: AI Nodule Detection and Diagnosis Outperforms Radiologists, Leading Models, and Standards Beyond Size and Growth Sylvain Bodard, Pierre Baudot, Benjamin Renoust, Charles Voyton, Gwendoline De Bie, Ezequiel Geremia, Van-Khoa Le, Danny Francis, Pierre-Henri Siot, Yousra Haddou, Vincent Bobin, Jean-Christophe Brisset, Carey C. Thomson, Valérie Bourdès, Benoit Huet Abstract Early detection of malignant lung nodules is critical, but its dependence on size and growth in screening inherently delays diagnosis. We present an AI system that redefines lung cancer screening by performing both detection and malignancy diagnosis directly at the nodule level on low-dose CT scans. To address limitations in dataset scale and explainability, we designed an ensemble of shallow deep learning and feature-based specialized models. Trained and evaluated on 25,709 scans with 69,449 annotated nodules, the system outperforms radiologists, Lung-RADS ® , and leading AI models (Sybil, Brock, Google, Kaggle). It achieves an area under the receiver operating characteristic curve (AUC) of 0.98 internally and 0.945 on an independent cohort. With 0.5 false positives per scan at 99.3% sensitivity, it addresses key barriers to AI adoption. Critically, it outperforms radiologists across all nodule sizes and stages—excelling in stage 1 cancers—and all growth-based metrics, including the least accurate: Volume-Doubling Time. It also surpasses radiologists by up to one year in diagnosing indeterminate and slow-growing nodules. keywords Lung Cancer Screening, CADe/CADx, Volume-Doubling Time, Nodule diameter, Lung-RADS, Volume growth, Nodule Detection, Nodule Characterization, Deep Neural Network Introduction Lung cancer is the leading cause of cancer deaths worldwide [ 1 , 2 ] . Early detection through low-dose computed tomography (LDCT) dramatically improves prognosis, enabling curative treatments [ 3 , 4 , 5 ] , reducing mortality by over 20% and tripling early-stage diagnoses, as demonstrated in pioneer National Lung Screening Trials such as NLST (US), NELSON (Netherlands-Belgium), and PanCan (Canada) [ 6 , 7 , 8 ] . As Lung Cancer Screening (LCS) programs are expanding globally [ 9 , 10 , 11 , 12 ] , new alarming trends emerged from Asian studies, with lung cancer comprising 60% of new cancer cases [ 13 ] . Lung-RADS ® guidelines and standard care rely on nodule size as the primary malignancy predictor, with the PanCan model confirming its dominance among predictive features [ 14 , 15 ] . Temporal size evolution also plays a crucial role, with Volume-Doubling Time (VDT) considered the “method of choice” for malignancy assessment [ 16 , 17 , 18 ] and currently recommended in Europe [ 19 , 20 ] . However, there is no consensus over VDT measure [ 14 ] and evidence for the longitudinal relevance of volumetric over diameter-based measures is still awaited [ 21 ] (see Creamer et al. [ 22 ] for instantaneous measure). Advances in quantitative imaging further reinforce its importance in clinical practice, as highlighted by Larici et al. , who stress that “size still matters” [ 23 , 14 ] . However, while morphological features contribute to malignancy prediction, their subjective nature and variability remain significant challenges [ 24 , 25 ] . Clinical trials from the UK and France highlight size and location as key factors in radiologist interpretation [ 26 , 27 ] . This continued reliance on size delays diagnosis until they meet predetermined criteria, i.e. size and growth thresholds and protocol-driven follow up over several months (as per NLST NELSON, LungRADs). This study focuses on the early detection and characterization of solid or part-solid parenchymal nodules (4–30 mm) [ 11 ] , as timely intervention for these lesions is critical to improving survival outcomes [ 29 ] . AI models—particularly deep neural networks—extract high-dimensional, multi-parametric features, including morphology, that are crucial for detecting early-stage malignancies, when nodules are smallest and treatment most effective. Lung cancer is a central focus of AI-driven diagnostic research owing to the disease’s global prevalence and the availability of open-access imaging data. To date, hundreds of AI models based on CT scans have been developed, with as many as 405 publications reviewed [ 30 , 31 ] . However, most models rely on a weak ground truth of radiologist assessments and suffer from an under-representation of early-stage cancer cases [ 21 ] , as is the case with the LIDC dataset [ 32 ] . Consequently, their effectiveness is inherently limited compared to models trained on histopathology-confirmed diagnoses, such as NLST (as verified by Ma et al. [ 33 ] ). Additionally, most computer-aided models are limited in scope, focusing exclusively on either nodule detection (CADe) or diagnosis (CADx), thereby limiting their clinical utility. To address this, we compare our model to Sybil [ 25 ] , Liao et al. (Kaggle Data Science Bowl winner; 1,972 , teams; \$1 M prizes) [ 35 ] , and Ardila et al. [ 9 ] —all trained on NLST and with proven superior performance in lung screening populations [ 37 ] . We also benchmark against the NLST Brock-Pancan model [ 15 , 38 ] , recommended by the British Thoracic Society. Unlike our model, however, it is a purely diagnostic tool (CADx), requiring radiologists to detect nodules and assess malignancy-related features such as size, attenuation, and spiculation. Despite AI advancements, clinical adoption of CAD systems remains hindered by high false positive (FP) rates, a major clinical concern [ 39 ] . Recent studies emphasize that “increased FP nodules remain a serious drawback” [ 40 ] and stress the need to improve AI specificity [ 41 ] . Furthermore, models by Liao et al. , Ardila et al. , and Sybil provide only patient-level malignancy predictions, failing to provide explicit, directly actionable and explainable CADe/CADx-based nodule-level assessments—still lacking in published lung CAD studies at the exception of Jia et al. recent study [ 42 ] . This prevents direct comparison of detection performance at nodule level. To address this gap, we compare our model to nnDetection, a self-configuring CAD model based on the nnU-Net design principles for detection tasks. nnDetection has demonstrated superior CADe performance, notably outperforming competitors in the LUNA16 nodule candidate-detection challenge [ 15 ] . Results Model and radiologist performances We evaluated the ability of our model to detect and characterize malignant lung nodules using two independent test sets: NLST (Test1, n=2159 ); and an Independent Cohort (IC, n=273 ). Fig. 1 provides model evaluation through Receiver Operating Characteristic (ROC) curves, Area Under the Curve (AUC), sensitivity, specificity, and accuracy at the Maximum Youden Index (MYI). The model achieved a patient-level AUC of 0.98 on Test1 (Confidence Intervals (CIs) provided in figures). Malignancy likelihood distributions for cancer and non-cancer patients are depicted in Supplementary Fig.1. Figure 1: Performance comparison: our model vs. radiologists, lung-RADS ® , and SOTA models: a. , Patient-level ROC curves for our model’s malignancy prediction on Test1 and Independent Cohort. Our model’s Operating points (OPs) at the Maximum Youden Index (MYI) are depicted with black tilted squares (in all panels of all figures except in d. where their colour match the colour of their corresponding curve). b. , Patient-level ROC curves for our model’s malignancy predictions on Test3 and Test4, compared with the mean of 4-Radiologists detection and Likelihood Of Malignancy assessment on Test3, as well as of six radiologists Lung-RADS ® 2019 score assessments

Read the complete text